Biotech Showcase™ 2017: Keryx looks to label expansion to drive Auryxia

January 19, 2017
After a stuttering launch and relaunch, Keryx Biopharmaceuticals CEO Greg Madison revealed to Mike Ward, Informa Pharma Intelligence’s insights global director of content, that Auryxia prescriptions picked up in 4Q 2016. The company plans to expand the drug’s label to treat iron deficiency in pre-dialysis patients while searching for additional nephrology assets during 2017.
Previous Video
Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III
Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

Founded as recently as 2014, Rexgenero is poised to start two Phase III trials of its lead candidate Rexmye...

Next Video
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients
Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duva...